开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2016-08-14 wanglong6789

审稿速度:2.0 | 投稿命中率:95.0
经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！
差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。
六天之后改完了，第三天就接收，目前等着上线；
具体时间表如下：
12 Aug 2016 Editor Decision - Accept
10 Aug 2016 AU - Revised PDF Built by Author
04 Aug 2016 Editor Decision - Major Revision
17 Jun 2016 AU - Author Submission
17 Jun 2016 AU - Original PDF Built by Author
希望对大家投稿有帮助！

386 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2023-12-25 qdhan_62149861 来自江苏省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：脑血管病
经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。

88 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2021-08-02 kiss可爱的筱杰

这个杂志支持共同通讯，大佬们

127 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2022-07-02 ms5000001930601839

去哪查询稿件提交状态？急求

97 0

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2021-11-28 145b138dm45暂无昵称

请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求

129 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2021-12-29 MS54455111222

如何判断两种药物之间是协同作用还是相加作用？

112 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2021-12-27 ms6000000264964247

如果文章发表了未提供ORCIDID如何添加？

105 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2020-07-23 ms4000000141889626

投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的

179 0

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2020-07-20 1467eb9bm20暂无昵称

好慢呀

231 0

[GetPortalCommentsPageByObjectIdResponse(id=525855, encodeId=6134525855f6, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投的关于脑血管病搭桥治疗复杂动脉瘤的文章，我们团队做的都是难度很高的动脉瘤手术，相对好发！ 差不多一个半月让修回，三个编委：第一位给提了7个问题，有大有小，非常中肯的建议；第二位就提了一个；第三位没提意见；所有编委都给予文章很高的评价，编辑部也说了发表的可能性很大。 六天之后改完了，第三天就接收，目前等着上线； 具体时间表如下： 12 Aug 2016 Editor Decision - Accept 10 Aug 2016 AU - Revised PDF Built by Author 04 Aug 2016 Editor Decision - Major Revision 17 Jun 2016 AU - Author Submission 17 Jun 2016 AU - Original PDF Built by Author 希望对大家投稿有帮助！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5GlsyGFsO0rlyJuBjY4iae1WIIxfxtOW80RPnGVCIdYsg/0, createdBy=d0bf83908, createdName=wanglong6789, createdTime=Sun Aug 14 11:36:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177140, encodeId=747e21e71401a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：脑血管病 经验分享：2023年帮这个杂志审稿过三篇稿子，均为日本学者的文章，同意发表两篇，拒稿一篇，相对还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6742222923, createdName=qdhan_62149861, createdTime=Mon Dec 25 20:21:55 CST 2023, time=2023-12-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1004712, encodeId=6e891004e12cc, content=这个杂志支持共同通讯，大佬们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/7EBE7D70085A594F52712A2C3E75751A/100, createdBy=2d802012020, createdName=kiss可爱的筱杰, createdTime=Mon Aug 02 17:55:05 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230089, encodeId=3f2612300891c, content=去哪查询稿件提交状态？急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=501f6411412, createdName=ms5000001930601839, createdTime=Sat Jul 02 09:27:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074726, encodeId=f23c10e472601, content=请问一下各位大佬，在哪里有这个杂志的参考文献endote格式？投稿时被退回来说参考文献要按要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5575080670, createdName=145b138dm45暂无昵称, createdTime=Sun Nov 28 10:28:47 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096079, encodeId=b27210960e937, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096080, encodeId=7c2c10960800f, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804218, encodeId=a7e9804218d1, content=投了一个临床回顾 6.11提交 7.20 外审结束 7.23拒稿一个悲伤的故事，不过审稿人的意见有些还是很中肯的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc35388626, createdName=ms4000000141889626, createdTime=Thu Jul 23 23:38:13 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803413, encodeId=730b803413bd, content=好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faaf5143294, createdName=1467eb9bm20暂无昵称, createdTime=Mon Jul 20 05:28:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801062, encodeId=7cc2801062ca, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：<a href='/topic/show?id=3b1484506af' target=_blank style='color:#2F92EE;'>#脊柱#</a>是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84506, encryptionId=3b1484506af, topicName=脊柱)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/ffbd7ae7f19a46d4bc76eadb164c5760/b3d082253d45492c9aa02bec640eb0af.jpg, createdBy=52185311019, createdName=drbob, createdTime=Fri Jul 03 11:56:24 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

2020-07-03 drbob

审稿速度:2.0 | 投稿命中率:50.0
经验分享：#脊柱#是个季刊，年文章数较少，我也是投稿后才发现的，审稿周期很可以，意见也很中肯

216 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务